A representative from medical technology company Medtronic tells mHealthWatch that the organization has secured U.S. Food and Drug Administration (FDA) clearance for MiniMed Connect.
MiniMed Connect is designed to provide a mobile connection to critical information for managing diabetes.
We’re told that the resource in question is the first product to enable people with diabetes to discreetly and conveniently view their insulin pump and continuous glucose monitor (CGM) data on a smartphone and provides remote monitoring and text message notifications for their loved ones.
It also gives healthcare teams more convenient access to more comprehensive patient data so they can adjust their patients’ care plans. The new product clearance was just announced from the American Diabetes Association 75th Scientific Sessions in Boston.
MiniMed Connect consists of a small device that easily fits on a keychain or in a pocket, a smartphone app for the person with diabetes, and a web display on desktop or mobile devices for their care partners. The MiniMed Connect device securely transmits pump and sensor glucose data from the patient’s MiniMed insulin pump to the app and web display, which shows real-time sensor glucose and insulin information on the phone or any Internet-enabled device anytime, anywhere.
“Engagement from people with diabetes, loved ones and healthcare providers is key to living well with diabetes. With MiniMed Connect, the entire care team can have access to critical diabetes data to inform the decisions that help people have better outcomes,” said Annette Brüls, vice president and general manager of Diabetes Services and Solutions at Medtronic.